SAGE Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the appointment of Thomas D. Anderson as chief commercial strategy officer. Mr. Anderson, former senior vice president, corporate strategy and commercial assessment at Shire plc, brings to SAGE more than 25 years of experience in the life science and healthcare-focused consumer packaged goods industries, with deep commercial expertise in the CNS field.
Help employers find you! Check out all the jobs and post your resume.
